Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Alumis Inc (ALMS)

Alumis Inc (ALMS)
6.20 x 2 9.60 x 12
Post-market by (Cboe BZX)
6.83 -1.21 (-15.05%) 04/10/25 [NASDAQ]
6.20 x 2 9.60 x 12
Post-market 6.83 unch (unch) 19:59 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
6.61
Day High
7.94
Open 7.85
Previous Close 8.04 8.04
Volume 329,900 329,900
Avg Vol 1,586,775 1,586,775
Stochastic %K 57.53% 57.53%
Weighted Alpha -69.36 -69.36
5-Day Change -1.71 (-20.02%) -1.71 (-20.02%)
52-Week Range 3.18 - 13.53 3.18 - 13.53
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 379,665
  • Shares Outstanding, K 47,222
  • Annual Sales, $ 0 K
  • Annual Income, $ -294,230 K
  • EBIT $ -236 M
  • EBITDA $ -233 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.48
  • Number of Estimates 4
  • High Estimate -1.07
  • Low Estimate -1.76
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.18 +114.78%
on 03/21/25
Period Open: 4.85
10.49 -34.89%
on 04/04/25
+1.98 (+40.82%)
since 03/10/25
3-Month
3.18 +114.78%
on 03/21/25
Period Open: 7.00
10.49 -34.89%
on 04/04/25
-0.17 (-2.43%)
since 01/10/25

Most Recent Stories

More News
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

SLRN : 2.15 (-1.15%)
ALMS : 6.83 (-15.05%)
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

Despite weak economic data, the S&P 500 (SPX) closed higher to start the new quarter, as traders await President Donald Trump’s tariff policy rollout. In the face of financial turbulence, several promising...

BIAF : 0.5601 (-10.48%)
JYD : 0.3333 (+21.33%)
QSG : 4.09 (+2.25%)
CAR : 70.87 (-4.13%)
WOR : 46.57 (-2.29%)
ALMS : 6.83 (-15.05%)
SLNO : 62.87 (-0.63%)
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

The S&P 500 (SPX) closed higher to start the new quarter, despite some weak economic data, as traders await for President Donald Trump’s tariff policy rollout. However, several promising small-cap companies...

BIAF : 0.5601 (-10.48%)
JYD : 0.3333 (+21.33%)
QSG : 4.09 (+2.25%)
CAR : 70.87 (-4.13%)
WOR : 46.57 (-2.29%)
ALMS : 6.83 (-15.05%)
SLNO : 62.87 (-0.63%)
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

ALMS : 6.83 (-15.05%)
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

ALMS : 6.83 (-15.05%)
Alumis to Present at Leerink's 2025 Global Healthcare Conference

ALMS : 6.83 (-15.05%)
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ALMS : 6.83 (-15.05%)
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ALMS : 6.83 (-15.05%)
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

ALMS : 6.83 (-15.05%)
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

ALMS : 6.83 (-15.05%)

Business Summary

Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN...

See More

Key Turning Points

3rd Resistance Point 8.97
2nd Resistance Point 8.46
1st Resistance Point 7.64
Last Price 6.83
1st Support Level 6.31
2nd Support Level 5.80
3rd Support Level 4.98

See More

52-Week High 13.53
Fibonacci 61.8% 9.58
Fibonacci 50% 8.35
Fibonacci 38.2% 7.13
Last Price 6.83
52-Week Low 3.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar